Friday, March 23, 2012

Synthon completes Phase I trial on Herceptin Biosimilar - Initiates Phase III trial

Roche's Herceptin (Trastuzumab) is a $6billion product globally and is approved for the treatment of HER2+ve breast cancer and gastric cancer. 
In all the in vitro and in vivo studies conducted so far, Synthon's Trastuzumab has shown similar behaviour in comparison with the reference product, Herceptin.. The outcome of the phase I clinical trial have confirmed these results, showing bio-equivalence of Synthon’s trastuzumab to Herceptin